Dr. Regueiro’s main clinical and research interest is inflammatory bowel disease (IBD), with a focus on the natural course of these diseases and postoperative prevention of Crohn’s disease. He has been instrumental in researching methods of prevention of postoperative Crohn’s disease and has led national and international research in the field. Due to his work, clinical pathways, guidelines, and algorithms of postoperative Crohn’s disease have been created. Recently, he has been involved in developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. This innovative healthcare delivery system has defined the concept of specialty medical home and will lead to further clinical programs and investigation of alternative models of care. Dr Regueiro is embarking on specialty care in population based health and integrating patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs. Dr. Regueiro has published extensively on the prevention and management of postoperative Crohn’s disease and genotype-phenotype correlations in IBD. He is the principal investigator on several multicenter, international research trials and conducts clinical research that defines the natural course and phenotypes of inflammatory bowel disease. Dr. Regueiro has developed a multidisciplinary IBD Center that operates as a state-of-the-art clinic for patients with Crohn’s disease and ulcerative colitis. Dr Regueiro has founded the IBD LIVE education series, which is the first virtual education platform in IBD that meets on a regular basis to include programs throughout the country. This work has been published as regular proceedings in the IBD journal and has led to additional innovative educational programs.
Selected publications from PubMed
Mirikizumab Long-Term Efficacy and Safety in Patients With Crohn's Disease: Results From the VIVID-2 Open-Label Extension Trial.
Sands BE, Barnes EL, D'Haens G, Hisamatsu T, Regueiro M, Kelly CR, Laharie D, Hozak RR, Yu G, Gandhi R A, Lopes MU, Durand F, Protic M, Moses RE, Vermeire S
Clin Gastroenterol Hepatol. 2026 Sep;24(9):2512-2523 doi: 10.1016/j.cgh.2026.01.049.
Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis.
Khasawneh O, Gerges KM, Khasawneh I, Savarino EV, Barberio B, Gadelmawla AF, Elhabbasi BM, Albandak M, Mohamed AT, Shlibek HA, Sawaf B, Regueiro M, Elhadi M
Dig Dis. 2026 Aug 18;:1-24 doi: 10.1159/000553479.
Reutilization of biologics for postoperative Crohn's disease recurrence prevention is effective.
Shah RS, Bachour SP, Xiao H, Yang Q, Weskamp G, Pothula S, Greenwood H, Patel M, Li T, Li E, Regueiro M, Barnes EL, Axelrad J, Click B, Cohen BL
Inflamm Bowel Dis. 2026 Aug 6 pii: izag157. doi: 10.1093/ibd/izag157.
Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments.
Rubin DT, Schreiber S, Peyrin-Biroulet L, Danese S, Gianfrancesco MA, Soonasra A, Sidhu S, Vranic I, Shelbaya A, Gruben D, Wei Y, Winthrop KL, Curtis JR, Regueiro MD, Dubinsky MC
Inflamm Bowel Dis. 2026 Jul 28 pii: izag142. doi: 10.1093/ibd/izag142.
Intestinal ultrasound to detect postoperative recurrence in patients with Crohn's disease: an international, multidisciplinary, RAND/UCLA appropriateness method study.
Ma C, Albashir S, Allocca M, de Buck van Overstraeten A, Kotze PG, Lu C, Maaser C, Maconi G, Panaccione R, Regueiro M, Rimola J, Spinelli A, Taylor SA, Wilkens R, Bemelman W, Cleveland NK, Gecse KB, Archer S, Kiarasi S, Cornfield LJ, Novak KL
Lancet Gastroenterol Hepatol. 2026 Jul;11(7):602-615 doi: 10.1016/S2468-1253(26)00082-8.
Help your network discover Dr. Miguel Regueiro's clinical expertise.
